Drug Trial Radar · NCT06198907
Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)
Last checked: Nov 20, 2026Latest source record: Jan 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
69
Planned (sponsor's estimate)
Start
Jan 2024
Primary completion
Dec 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Dizal Pharmaceuticals
- First posted
- Jan 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in combination with sintilimab as the front-line treatment for patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC)
Conditions
- Non-Small-Cell Lung Cancer
Interventions
GolidocitinibDrug
Daily dosing of golidocitinib
SintilimabDrug
Sintilimab, 200mg, intravenous, every 3 weeks.
platinum doublet chemotherapyDrug
Pemetrexed or nab-paclitaxel +carboplatin, intravenous, every 3 weeks for 2 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (ORR) (cohort1)Time frame: through study completion, an average of 1 year
- Progression-free survival (PFS) (cohort2)Time frame: through study completion, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.